PRS1 PREVALENCE AND TREATMENT OF COPD IN GERMANY von Höer, A, Gothe, H, Storz, P, Sandtmann, R, Häussler, B

Volltext

PRS3 COST-EFFECTIVENESS OF ROFLUMILAST IN THE UK:A 1-YEAR STUDY IN PATIENTS WITH SEVERE TO VERY SEVERE COPD von Van Nooten, F, Rutten-van Molken, M, Lindemann, M, Sandtmann, R

Volltext

PRS2 PRESCRIPTION PATTERNS IN COPD PATIENTS IN A GERMAN SICKNESS FUND POPULATION von Gothe, H, Sandtmann, R, Hoeer, A, Schiffhorst, G, Storz, P, Glaeske, G, Haeussler, B

Volltext

PMD22 EPIDEMIOLOGY AND PHARMAECONOMY OF COPD ACROSS EUROPE von Sandtmann, R, Nowak, D, Schramm, B, Kilgert, K, Berger, K

Volltext

PCOI DRUG USE PROFILES AFTER HOSPITALIZARON FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE NETHERLANDS AND THE RISK ON RE-HOSPITALIZATION von Janse, AFC, Breekveldt-Postma, NS, Erkens, JA, Sandtmann, R, Melilli, LE, Herings, RMC

Volltext